bluebird bio (BLUE) Projected to Post Quarterly Earnings on Monday

bluebird bio (NASDAQ:BLUE) will likely be posting its quarterly earnings results on Monday, March 24th. Analysts expect bluebird bio to post earnings of ($6.30) per share and revenue of $27.07 million for the quarter.

bluebird bio Price Performance

BLUE stock opened at $3.90 on Friday. The company has a market capitalization of $37.92 million, a PE ratio of -0.10 and a beta of 0.76. The stock’s 50 day moving average is $5.97 and its two-hundred day moving average is $8.00. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. bluebird bio has a 52-week low of $3.56 and a 52-week high of $28.60.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Wells Fargo & Company reduced their price objective on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Monday, February 24th. JPMorgan Chase & Co. raised shares of bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. Barclays increased their price objective on shares of bluebird bio from $2.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, December 31st. Baird R W lowered shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 21st. Finally, StockNews.com started coverage on shares of bluebird bio in a research note on Thursday. They issued a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, bluebird bio currently has an average rating of “Hold” and a consensus price target of $51.00.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.